The largest community of pharma leaders

Aperio Hires CAR-T Trials Expert Jonathan Yusi to Support Cell and Gene Therapy Studies

RESEARCH TRIANGLE PARK, N.C.–()–Aperio Clinical Outcomes, a leading clinical research organization (CRO), announced today that Jonathan Yusi, an expert in the coordination and management of cell and gene therapy clinical trials, has joined the company as Senior Clinical Trials Manager to support their biotechnology clients in the immuno-oncology space.

Yusi has been managing immune-based therapy trials for over seven years. Prior to joining Aperio, he was a program manager for CAR-T studies and oversaw the first CAR-T program at a large CRO. He has provided independent trial management consulting for CAR-T trials, and his expertise has resulted in lasting KOL relationships within the immuno-oncology space. In addition to his adoptive cell therapy knowledge, Yusi brings over 20 years of clinical research experience to Aperio, with a focus on trial logistics, management, and monitoring of targeted and immune therapies in oncology trials.

Says Suzanne Kincaid, Aperio’s COO and an oncology industry veteran herself, “FDA expects to see over 200 INDs for cell and gene therapies in 2020, so it is imperative that our biotech clients have expertise like Jonathan’s to manage their trials. He has a strong understanding of the complexities of cell and gene therapy studies and can break down the components for ideal study set-up. We are so excited to have Jonathan help our immuno-oncology clients as they explore these groundbreaking treatments.”

“Cell and gene therapy trials are a logistical maze, and one missed endpoint can be catastrophic to the study,” says Yusi. “These programs allow me to utilize everything I’ve learned about clinical research and oncology, and my medical and scientific background brings an understanding to the science behind the treatments. The bulk of my career has involved oncology trials, so as the treatments have evolved and become more personalized, my experience has evolved as well. These are life-saving breakthroughs, and I’m happy to bring this experience to Aperio and our immune-based therapy clients.”

About Aperio Clinical Outcomes

In a data driven industry, Aperio remains dedicated to transparency with clients and focused on the most important part of the process: people. Aperio provides full, customizable clinical research services across multiple therapeutic areas, as well as consulting services in Quality Assurance, Strategic Resourcing and Clinical Trial Technology. For more information:


Recent Articles

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...

TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals comments on animal studies in the development...

TTG Welcomes Bruce Anneaux to the Executive Team

HIGGINSVILLE, Mo.--(BUSINESS WIRE)-- #airadigmadventure--TTG has hired Dr. Bruce Anneaux as the...

Free, Automated Identification of Financial Aid for COVID-19 Treatment: Atlas Health Helps Hospitals, Uninsured & Underinsured Patients Mitigate “Surprise” Bills

SAN FRANCISCO--(BUSINESS WIRE)--Free, Automated Identification of Financial Aid for COVID Treatment:...

Zelis and Concert Genetics Launch Genetic Testing Claim Editing Solution

BEDMINSTER, N.J. & NASHVILLE, Tenn.--(BUSINESS WIRE)-- #HealthcareIndustry--Zelis, the healthcare industry’s leading...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.